

ALL. B

Decreto Rettore Università di Roma “La Sapienza” n 1828/2018 del 12/07/2018

ENKE BALDINI

Curriculum Vitae

Place: Roma

Date: 20/08/2018

Part I – Education

Type	Year	Institution	Notes (Degree, Experience,...)
University graduation	2001	University of L'Aquila	Biological Sciences cum laude
PhD	2005	University of L'Aquila	Experimental Medicine and Endocrinology
Licensure 01	2002	University of L'Aquila	Licensed to practice as biologist
Licensure 02	2017	MIUR	ASN for the SC 06/A2

Part II – Appointments

IIA – Academic Appointments

Start	End	Institution	Position
2007	2007	Complex Operative Unit of Endocrinology, Policlinic Umberto I, Roma	Postdoctoral Fellowship
2008	2008	Dept. Experimental Medicine, University “Sapienza” of Roma	Research contract
2009	2010	Dept. Experimental Medicine, University “Sapienza” of Roma	Research contract
2010	2010	Dept. Experimental Medicine, University “Sapienza” of Roma	Research contract
2009	2011	Université de Rennes 1	Invited professor
2011	2014	Dept. Experimental Medicine, University “Sapienza” of Roma	Contract of fixed time researcher (art. 1, comma 14, law 4 november 2005, n. 230)
2014	2015	Dept. Experimental Medicine, University “Sapienza” of Roma	Research fellowship
2018	2019	Dept. Surgical Sciences, University “Sapienza” of Roma	Research fellowship

IIB – Other Appointments

Start	End	Institution/Company	Position
2007	2007	Centre de Recherche d'Etudes Biologiques Sociales et Scientifiques (C.R.E.B.S.), Rennes, France	Chargée d'Etudes
2015	2015	Luigi Maria Monti Foundation	Research contract
2016	2016	Luigi Maria Monti Foundation	Research contract

Part III – Editorial Board membership, Awards and Honors

Year	Title
2003	Best Poster Award – 30° National Congress of the Italian Society of Endocrinology
2014	Member of the Editorial Board of “Austin Journal of Pathology & Laboratory Medicine”
2017	Top reviewer for Sapienza University of Rome (in field Pharmacology, Toxicology and Pharmaceutics)

Part IV - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Grant value
2004	Characterization of matrix metalloproteinases, Fas and Fas ligand in human testicular tumors.	PRIN 2004 (Investigator)	46.500 €
2004	Molecular mechanisms involved in the pathogenesis of thyroid tumors.	University Research 2004 (ex 60%) - University of L'Aquila (Investigator)	7.000 €
2004	From molecules to man: biotechnological application of space research (MoMa)	Research project of the Italian Space Agency (Investigator)	105.000 €
2011	Papillary and medullary thyroid carcinomas incurable with conventional therapies: clinical and epidemiological characteristics, synthesis, preclinical pharmacology, target-therapy of new agents that inhibit tyrosine kinases and Aurora kinases in human primary cell cultures.	PRIN 2010-2011 (Investigator)	124.543 €
2012	Expression of members of the Aurora kinase family and their evaluation as new molecular targets for the therapy of medullary thyroid carcinomas.	University research 2012 “Sapienza” University of Rome (Investigator)	6.000 €

2014	Expression study of the different isoforms of the TACC1 protein in normal and tumor thyroid tissues	Research Grant by the University "Sapienza" of Roma (Principal investigator)	3000 €
------	---	--	--------

Part V – Research Activities

Keywords	Brief Description
Fertility	
Thyroid	
Thyroid cancer diagnosis and prognosis	
Aurora kinases	
Molecular targeted therapy	<p>Dr. Enke Baldini started her research activity with an investigation concerning the effects of iodine supplementation on fertility of sheep living in iodine deficient areas, documenting as an adequate iodine prophylaxis program was capable of increasing sheep fertility. Over the years, her research activity has been mainly focused on the physiopathology of the thyroid gland. In particular, she has been involved in research projects aimed to define the molecular pathogenesis of thyroid cancers (TC). In this context, she evaluated the expression of enzymes involved in the degradation of ECM, that is metalloproteinases and the plasminogen activating system. These studies demonstrated for the urokinase plasminogen activator (uPA) and its cognate receptor (uPAR) a relevant prognostic role in papillary TC, better than clinicopathological parameters currently used in clinical practice. Moreover, Enke Baldini has been engaged in the search of a new therapeutic approach for the treatment of the highly aggressive anaplastic TC (ATC), which has led to the identification of members of the Aurora kinase family as possible therapeutic targets. Similar encouraging results emerged from other studies performed by her on testicular germ cell tumors. Enke Baldini investigated TC also from a diagnostic perspective, documenting the usefulness of mRNA and/or protein detection of thyroid markers (i.e. thyroglobulin and calcitonin) in the washout of fine needle aspiration biopsy for the diagnosis of metastatic TC. Recently, she participated in cross-sectional studies that evidenced in women affected by either benign or malignant thyroid diseases a greater risk of extrathyroidal cancers, especially breast cancer. She has been also involved in research projects aimed to elucidate the role of TH on fertility.</p>

Part VI – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	59	SCOPUS/Web of Science	2003	2018
Papers [national]	1		2006	2006
Book chapters [scientific]	6		2008	2018
Total Impact factor	171.53			
Median Impact Factor	2.907			
Total Citations	906			

Average Citations per Product	15.36
Hirsch (H) index	16
Normalized H index*	1.07
Contemporary H index	11

*H index divided by the academic seniority.

Bibliometric indicators relative to the acquisition of the National Scientific Qualification for Associate Professor:

- Number of publications in the last 5 years: **37**
- Number of citations in the last 10 years: **879**
- h-index of the last 10 years: **13**

Part VII– Reviewer's activity

The reviewer's activity for the following international scientific journals has been verified and certified by Publons (<https://publons.com/>):

Journal	Number of Reviews
Clinical Cancer Research	3
International Journal of Molecular Sciences	2
Biomedicine & Pharmacotherapy	2
The International Journal of Biochemistry & Cell Biology	1
Cellular Physiology and Biochemistry	1
Expert Review of Anticancer Therapy	1
Molecular Cancer Therapeutics	1
EBioMedicine	1
Data in Brief	1
Laryngoscope Investigative Otolaryngology	1

Part VIII– Selected Publications

The reported journal's Impact factor (IF) is relative to the year of publication.

1. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Y. Arlot-Bonnemains, **E. Baldini**, B. Martin, JG. Delcros, M. Toller, F. Curcio, F.S. Ambesi-Impiombato, M. D'Armiento, S. Ulisse. *Endocrine-Related Cancer* 15:559-568, 2008.
IF: 4.805; Citations: 47
2. The urokinase plasminogen activator system: a target for anti-cancer therapy. S. Ulisse, **E. Baldini**, S. Sorrenti, M. D'Armiento. *Current Cancer Drug Targets* 9:32-71, 2009.
IF: 3.522; Citations: 181
3. Expression of Fas and Fas ligand in human testicular germ cell tumors. **E. Baldini**, S. Ulisse, E. Marchionni, A. Di Benedetto, G. Giovannetti, E. Petrangeli, S. Sentinelli, R. Perrone Donnorso, M.G. Reale, M. Mottolese, L. Gandini, A. Lenzi, M. D'Armiento. *International Journal of Andrology* 32:127-130, 2009.

IF: 3.695; Citations: 6

4. TSH receptor and thyroid specific genes expression in human skin.
F. Cianfarani*, **E. Baldini***, A. Cavalli, E. Marchioni, L. Lembo, M. Teson, S. Persechino, G. Zambruno, S. Ulisse, T. Odorisio, M. D'Armiento. *Journal of Investigative Dermatology* 130:93-101, 2010.
*The first two authors provided an equal contribution
IF: 6.525; Citations: 52
5. Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas.
S. Ulisse, **E. Baldini**, M. Mottolese, S. Sentinelli, P. Gargiulo, V. Brancato, S. Sorrenti, A. Di Benedetto, E. De Antoni, M. D'Armiento. *BMC Cancer* 10:151, 2010.
IF: 3.362; Citations: 10
6. Dereulation of Aurora kinases genes expression in human testicular germ cell tumors.
E. Baldini, Y. Arlot-Bonnemains, M. Mottolese, S. Sentinelli, B. Antoniani, S. Sorrenti, M. Salducci, E. Comini, S. Ulisse, M. D'Armiento. *Andrologia* 42:260-267, 2010.
IF: 1.630; Citations: 12
7. Inhibition of the Aurora kinases suppresses in vitro NT2-D1 cell growth and tumorigenicity.
S. Ulisse, Y. Arlot-Bonnemains, **E. Baldini**, S. Morrone, S. Carocci, L. Di Luigi, M. D'Armiento. *Journal of Endocrinology* 204:135–142, 2010.
IF: 3.718; Citations: 10
8. Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT.
E. Baldini, Y. Arlot-Bonnemains, S. Sorrenti, C. Mian, M.R. Pelizzo, E. De Antoni, S. Palermo, S. Morrone, S. Barollo, A. Nesca, C.G. Moretti, M. D'Armiento, S. Ulisse. *BMC Cancer* 11:411, 2011.
IF: 3.362; Citations: 17
9. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
S. Ulisse*, **E. Baldini***, S. Sorrenti, S. Barollo, L. Gnessi, A. Catania, MR Pellizzo, F. Nardi, C. Mian, E. De Antoni, M. D'Armiento, L. Frati. *Journal of Clinical Endocrinology & Metabolism* 96:504-508, 2011.
*The first two authors provided an equal contribution
IF: 6.209; Citations: 32
10. Aurora-C interacts with and phosphorylates the transforming acidic coiled-coil 1 protein.
J.C. Gabillard, S. Ulisse, **E. Baldini**, S. Sorrenti, J.Y. Cremet, C. Coccaro, C. Prigent, M. D'Armiento, Y. Arlot-Bonnemains. *Biochemical and Biophysical Research Communication* 408:647-653, 2011.
IF: 2.297; Citations: 16
11. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
S. Ulisse*, **E. Baldini***, S. Sorrenti, S. Barollo, N. Prinzi, A. Catania, A. Nesca, L. Gnessi, M.R. Pelizzo, C. Mian, C. De Vito, A. Calvanese, S. Palermo, S. Persechino, E. De Antoni, M. D'Armiento. *Clinical Endocrinology* 77:780-786, 2012.

*The first two authors provided an equal contribution

IF: 3.457; **Citations:** 29

12. Cervical lymph node metastases from thyroid cancer: does thyroglobulin and calcitonin measurement in fine needle aspirates improve the diagnostic value of cytology?
E. Baldini, S. Sorrenti, C. Di Gioia, C. De Vito, A. Antonelli, L. Gnessi, G. Carbotta, E. D'Armiento, P. Miccoli, E. De Antoni, S. Ulisse. *BMC Clinical Pathology* 13:7, 2013.
IF: not available; **Citations:** 25
13. Effects of Ultraviolet Radiation on FRTL-5 Cell Growth and Thyroid-Specific Gene Expression.
E. Baldini, M. D'Armiento, S. Sorrenti, M. Del Sordo, R. Mocini, S. Morrone, L. Gnessi, F. Curcio, S. Ulisse. *Astrobiology* 13:536-542, 2013.
IF: 2.585; **Citations:** 1
14. The dual aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity.
E. Baldini, C. Tuccilli, N. Prinzi, S. Sorrenti, A. Antonelli, L. Gnessi, A. Catania, C. Moretti, R. Mocini, G. Carbotta, S. Morrone, S. Persechino, A. Redler, E. De Antoni, M. D'Armiento, S. Ulisse. *Journal of Biological Regulators & Homeostatic Agents* 27:705-715, 2013.
IF: 2.040; **Citations:** 5
15. Prevalence of breast cancer in thyroid diseases: results of a cross-sectional study of 3,921 patients.
N. Prinzi, **E. Baldini**, S. Sorrenti, C. De Vito, C. Tuccilli, A. Catania, S. Carbotta, R. Mocini, C. Coccaro, A. Nesca, M. Bianchini, E. De Antoni, M. D'Armiento, S. Ulisse. *Breast Cancer Research and Treatment* 144:683-688, 2014.
IF: 4.198; **Citations:** 14
16. Molecular basis of thyrotropin and thyroid hormone action during implantation and early development.
M. Colicchia, L. Campagnolo, **E. Baldini**, S. Ulisse, H. Valensise, C. Moretti. *Human Reproduction Update* 20:884-904, 2014.
IF: 10.165; **Citations:** 39
17. Emerging molecular markers for the prognosis of differentiated thyroid cancer patients.
E. Baldini, S. Sorrenti, C. Tuccilli, N. Prinzi, C. Coccaro, A. Catania, A. Filippini, M. Bononi, E. De Antoni, M. D'Armiento, S. Ulisse. *International Journal of Surgery* 12(Suppl.1):S52-56, 2014.
IF: 1.650; **Citations:** 10
18. The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways.
S. Barollo, L. Bertazza, **E. Baldini**, S. Ulisse, E. Cavedon, M. Boscaro, R. Pezzani, C. Mian. *Investigational New Drugs* 32:626-635, 2014.
IF: 2.927; **Citations:** 13
19. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
E. Baldini, C. Tuccilli, N. Prinzi, S. Sorrenti, A. Antonelli, L. Gnessi, S. Morrone, C. Moretti, M. Bononi, Y. Arlot-Bonnemains, M. D'Armiento, S. Ulisse. *Endocrine-Related Cancer* 21:797-811, 2014.

IF: 4.805; Citations: 13

20. Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients.
E. Baldini, C. Tuccilli, N. Prinzi, S. Sorrenti, L. Falvo, C. De Vito, A. Catania, R. Mocini, C. Coccaro, S. Alessandrini, S. Barollo, C. Mian, A. Antonelli, E. De Antoni, M. D'Armiento, S. Ulisse. *PloS One* 10:e0121514, 2015.
IF: 3.234; Citations: 11
21. Association of thyroid diseases with primary extra-thyroidal malignancies in women: results of a cross-sectional study of 6,386 patients.
N. Prinzi, S. Sorrenti, **E. Baldini**, C. De Vito, C. Tuccilli, A. Catania, C. Coccaro, M. Bianchini, A. Nesca, G. Grani, R. Mocini, E. De Antoni, M. D'Armiento, S. Ulisse. *PloS One* 10:e0122958, 2015.
IF: 3.234; Citations: 8
22. Papillary thyroid cancer is characterized by the altered expression of genes involved in the sumoylation process.
C. Tuccilli*, **E. Baldini***, S. Sorrenti, C. di Gioia, D. Bosco, V. Ascoli, C. Mian, S. Barollo, R. Rendina, C. Coccaro, M. Pepe, A. Catania, M. Bononi, F. Tartaglia, E. De Antoni, M. D'Armiento, S. Ulisse. *Journal of Biological Regulators & Homeostatic Agents* 29:655-662, 2015.
* The first two authors provided an equal contribution
IF: 2.040; Citations: 3
23. Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma derived cell line.
C. Tuccilli*, **E. Baldini***, N. Prinzi, S. Morrone, S. Sorrenti, A. Filippini, A. Catania, S. Alessandrini, R. Rendina, C. Coccaro, M. D'Armiento, S. Ulisse *Endocrine* 52:287-95, 2016.
*The first two authors provided an equal contribution
IF: 3.878; Citations: 2
24. Nodular thyroid disease in the elderly: novel molecular approaches for the diagnosis of malignancy. S. Sorrenti, **E. Baldini**, F. Tartaglia, A. Catania, S. Arcieri, D. Pironi, P.G. Calò, A. Filippini, S. Ulisse: *Aging Clinical and Experimental Research* 29(Suppl 1):7-13, 2017.
IF: 2.121; Citations: 5
25. Deregulated expression of VHL mRNA variants in papillary thyroid cancer.
E. Baldini, C. Tuccilli, Y. Arlot-Bonnemains, F. Chesnel, S. Sorrenti, C. De Vito, A. Catania, E. D'Armiento, A. Antonelli, P. Fallahi, S. Watutantrige-Fernando, F. Tartaglia, S. Barollo, C. Mian, M. Bononi, S. Arcieri, D. Mascagni, M. Vergine, D. Pironi, M. Monti, A. Filippini, S. Ulisse. *Molecular and Cellular Endocrinology* 443:121-127, 2017.
IF: 3.563; Citations: 2
26. Expression and prognostic value of the cell polarity PAR complex members in thyroid cancer.
C. Tuccilli*, **E. Baldini***, Y. Arlot-Bonnemains, F. Chesnel, S. Sorrenti, C. De Vito, E. D'Armiento, A. Antonelli, P. Fallahi, S. Watutantrige, F. Tartaglia, S. Barollo, C. Mian, M. Bononi, S. Arcieri, D. Mascagni, D. Pironi, M. Vergine, M. Monti, A. Filippini, S. Ulisse. *International Journal of Oncology* 50:1413-1422, 2017.
* The first two authors provided an equal contribution
IF: 3.333; Citations: 1

27. Thyroid hormone regulates protease expression and activation of Notch signaling in implantation.
D. Piccirilli*, **E. Baldini***, M. Massimiani, A. Camaioni, A. Salustri, R. Bernardini, M. Centanni, S. Ulisse, C. Moretti, L. Campagnolo. *Journal of Endocrinology* 236:1-12, 2018.
* The first two authors provided an equal contribution
IF: 4.012; **Citations:** 1
28. Iodine deficiency in pregnancy: still a health issue for the women of Cassino city.
C. Tuccilli*, **E. Baldini***, E. Truppa, B. D'Auria, D. De Quattro, G. Cacciola, T. Aceti, G. Cirillo, A. Faiola, P. Indigeno, L. D'Aliesio, F. Gazzellone, M. Bononi, E. D'Armiento, G. Carbotta, D. Pironi, A. Catania, S. Sorrenti, S. Ulisse. *Nutrition* 50:60-65, 2018.
* The first two authors provided an equal contribution
IF: 3.734; **Citations:** 1
29. CTLA-4 and PD-1 ligands gene expression in epithelial thyroid cancers.
C. Tuccilli*, **E. Baldini***, S. Sorrenti, A. Catania, A. Antonelli, P. Fallahi, F. Tartaglia, S. Barollo, C. Mian, A. Palmieri, G. Carbotta, S. Arcieri, D. Pironi, M. Vergine, M. Monti, S. Ulisse. *International Journal of Endocrinology*, 2018: 1742951, 2018.
* The first two authors provided an equal contribution
IF: 2.340; **Citations:** 0
30. Thyroid diseases and skin autoimmunity.
E. Baldini, T. Odorisio, C. Tuccilli, S. Persechino, S. Sorrenti, A. Catania, D. Pironi, G. Carbotta, L. Giacomelli, S. Arcieri, M. Vergine, M. Monti, S. Ulisse. *Reviews in Endocrine and Metabolic Disorders* In press, 2018.
IF: 4.963; **Citations:** 0

Part IX– Complete list of publications

Publication on international journals

1. N. Ferri, S. Ulisse, F. Aghini-Lombardi, F.M. Graziano, T. Di Mattia, F.P. Russo, M. Arizzi, **E. Baldini**, P. Trimboli, D. Attanasio, A. Fumarola, A. Pinchera and M. D'Armiento: Iodine supplementation restores fertility of sheep exposed to iodine deficiency. *Journal of Endocrinological Investigation* 26:1081-1087, 2003.
2. P. D'Abizio, **E. Baldini**, P.F. Russo, L. Biordi, F.M. Graziano, N. Rucci, G. Properzi, S. Francavilla, S. Ulisse: Ontogenesis and cell specific localization of Fas ligand expression in the rat testis. *International Journal of Andrology* 27:1-7, 2004.
3. **E. Baldini**, M. Toller, F.M. Graziano, F.P. Russo, M. Pepe, L. Biordi, E. Marchioni, F. Curcio, S. Ulisse, F.S. Ambesi-Impiombato, M. D'Armiento: Expression of matrix metalloproteinases and their specific inhibitors (TIMPs) in normal and different human thyroid tumor cell lines. *Thyroid* 14:881-888, 2004.
4. S. Ulisse, **E. Baldini**, M. Toller, E. Marchioni, L. Giacomelli, E. De Antoni, E. Ferretti, E. Marzullo, F.M. Graziano, P. Trimboli, L. Biordi, F. Curcio, A. Gulino, F.S. Ambesi-Impiombato, M. D'Armiento: Differential expression of the components of the plasminogen

- activating system in human thyroid tumour derived cell lines and papillary carcinomas. *European Journal of Cancer* 42:2631-2638, 2006.
5. S. Ulisse, J-G Delcros, **E. Baldini**, M. Toller, F. Curcio, L. Giacomelli, C. Prigent, F.S. Ambesi-Impiombato, M. D'Armiento, Y. Arlot-Bonnemains: Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. *International Journal of Cancer* 119:275-282, 2006.
 6. S. Ulisse, **E. Baldini**, M. Toller, J-G. Delcros, A. Guého, F. Curcio, E. De Antoni, L. Giacomelli, F.S. Ambesi-Impiombato, S. Bocchini, M. D'Armiento, Y. Arlot-Bonnemains: Transforming Acidic Coiled-Coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. *Endocrine-Related Cancer* 14:827-837, 2007.
 7. Y. Arlot-Bonnemains, **E. Baldini**, B. Martin, JG. Delcros, M. Toller, F. Curcio, F.S. Ambesi-Impiombato, M. D'Armiento, S. Ulisse: Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. *Endocrine-Related Cancer* 15:559-568, 2008.
 8. S. Ulisse, **E. Baldini**, S. Sorrenti, M. D'Armiento: The urokinase plasminogen activator system: a target for anti-cancer therapy. *Current Cancer Drug Targets* 9:32-71, 2009.
 9. **E. Baldini**, S. Ulisse, E. Marchioni, A. Di Benedetto, G. Giovannetti, E. Petrangeli, S. Sentinelli, R. Perrone Donnorso, M.G. Reale, M. Mottolese, L. Gandini, A. Lenzi, M. D'Armiento: Expression of Fas and Fas ligand in human testicular germ cell tumors. *International Journal of Andrology* 32:127-130, 2009.
 10. S. Ulisse, **E. Baldini**, M. Mottolese, S. Sentinelli, P. Gargiulo, V. Brancato, S. Sorrenti, A. Di Benedetto, E. De Antoni, M. D'Armiento: Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas. *BMC Cancer* 10:151, 2010.
 11. F. Cianfarani*, **E. Baldini***, A. Cavalli, E. Marchioni, L. Lembo, M. Teson, S. Persechino, G. Zambruno, S. Ulisse, T. Odorisio, M. D'Armiento: TSH receptor and thyroid specific genes expression in human skin. *Journal of Investigative Dermatology* 130:93-101, 2010.
* The first two authors provided an equal contribution
 12. **E. Baldini**, Y. Arlot-Bonnemains, M. Mottolese, S. Sentinelli, B. Antoniani, S. Sorrenti, M. Salducci, E. Comini, S. Ulisse, M. D'Armiento: Deregulation of Aurora kinases genes expression in human testicular germ cell tumors. *Andrologia* 42:260-267, 2010.
 13. S. Ulisse, Y. Arlot-Bonnemains, **E. Baldini**, S. Morrone, S. Carocci, L. Di Luigi, M. D'Armiento: Inhibition of the Aurora kinases suppresses *in vitro* NT2-D1 cell growth and tumorigenicity. *Journal of Endocrinology* 204:135-142, 2010.
 14. **E. Baldini**, Y. Arlot-Bonnemains, S. Sorrenti, C. Mian, M.R. Pellizzo, E. De Antoni, S. Palermo, S. Morrone, S. Barollo, A. Nesca, C.G. Moretti, M. D'Armiento, S. Ulisse: Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses *in vitro* growth and tumorigenicity of the MTC derived cell line TT. *BMC Cancer* 11:411, 2011.
 15. S. Ulisse*, **E. Baldini***, S. Sorrenti, S. Barollo, L. Gnessi, A. Catania, MR Pellizzo, F. Nardi, C. Mian, E. De Antoni, M. D'Armiento, L. Frati: High expression of the urokinase

plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. *Journal of Clinical Endocrinology & Metabolism* 96:504-508, 2011.

* The first two authors provided an equal contribution

16. J.C. Gabillard, S. Ulisse, **E. Baldini**, S. Sorrenti, J.Y. Cremet, C. Coccaro, C. Prigent, M. D'Armiento, Y. Arlot-Bonnemains: Aurora-C interacts with and phosphorylates the transforming acidic coiled-coil 1 protein. *Biochemical and Biophysical Research Communication* 408:647-653, 2011.
17. S. Ulisse*, **E. Baldini***, S. Sorrenti, S. Barollo, N. Prinzi, A. Catania, A. Nesca, L. Gnessi, M.R. Pelizzo, C. Mian, C. De Vito, A. Calvanese, S. Palermo, S. Persechino, E. De Antoni, M. D'Armiento: In papillary thyroid carcinoma BRAF^{V600E} is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval. *Clinical Endocrinology* 77:780-786, 2012.
* The first two authors provided an equal contribution
18. **E. Baldini**, S. Sorrenti, E. D'Armiento, F.M. Di Matteo, A. Catania, S. Ulisse: The urokinase plasminogen activating system in thyroid cancer: clinical implications. *Giornale di Chirurgia* 33:305-310, 2012.
19. **E. Baldini**, S. Sorrenti, E. D'Armiento, E. Guaitoli, S. Morrone, V. D'Andrea, L. Gnessi, C. Moretti, A. Antonelli, A. Catania, E. De Antoni, S. Ulisse: Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines. *Clinica Terapeutica* 163:e307-313, 2012.
20. S. Sorrenti, E. Guaitoli, A. Catania, V. D'Andrea, F.M. Di Matteo, M. Nardi, N. Prinzi, F. Nardi, V. Ascoli, **E. Baldini**, S. Ulisse, E. De Antoni: Surgical strategies in patients with medullary thyroid carcinoma. *Clinica Terapeutica* 163:e303-306, 2012.
21. **E. Baldini**, S. Sorrenti, A. Catania, E. Guaitoli, N. Prinzi, R. Mocini, F. Nardi, E. D'Armiento, M. Bianchini, F.M. Di Matteo, M. Ruggieri, E. De Antoni, S. Ulisse: Diagnostic utility of thyroglobulin measurement in the fine needle aspirates from cervical lymph nodes: a case report. *Giornale di Chirurgia* 10:305-310, 2012.
22. **E. Baldini**, S. Sorrenti, E. D'Armiento, N. Prinzi, E. Guaitoli, L. Gnessi, C. Moretti, M. Bianchini, S. Alessandrini, A. Catania, E. De Antoni, S. Ulisse: Aurora kinases: new molecular targets in thyroid cancer therapy. *Clinica Terapeutica* 163:e457-462, 2012.
23. **E. Baldini**, S. Sorrenti, C. Di Gioia, C. De Vito, A. Antonelli, L. Gnessi, G. Carbotta, E. D'Armiento, P. Miccoli, E. De Antoni, S. Ulisse: Cervical lymph node metastases from thyroid cancer: does thyroglobulin and calcitonin measurement in fine needle aspirates improve the diagnostic value of cytology? *BMC Clinical Pathology* 13:7, 2013.
24. **E. Baldini**, M. D'Armiento, S. Sorrenti, M. Del Sordo, R. Mocini, S. Morrone, L. Gnessi, F. Curcio, S. Ulisse: Effects of Ultraviolet Radiation on FRTL-5 Cell Growth and Thyroid-Specific Gene Expression. *Astrobiology* 13:536-542, 2013.
25. **E. Baldini**, C. Tuccilli, N. Prinzi, S. Sorrenti, A. Antonelli, L. Gnessi, A. Catania, C. Moretti, R. Mocini, G. Carbotta, S. Morrone, S. Persechino, A. Redler, E. De Antoni, M. D'armiento, S. Ulisse: The dual aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell

growth and tumorigenicity. *Journal of Biological Regulators & Homeostatic Agents* 27:705-715, 2013.

26. N. Prinzi, **E. Baldini**, S. Sorrenti, C. De Vito, C. Tuccilli, A. Catania, S. Carbotta, R. Mocini, C. Coccaro, A. Nesca, M. Bianchini, E. De Antoni, M. D'Armiento, S. Ulisse: Prevalence of breast cancer in thyroid diseases: results of a cross-sectional study of 3,921 patients. *Breast Cancer Research and Treatment* 144:683-688, 2014.
27. M. Colicchia, L. Campagnolo, **E. Baldini**, S. Ulisse, H. Valensise, C. Moretti: Molecular basis of thyrotropin and thyroid hormone action during implantation and early development. *Human Reproduction Update* 20:884-904, 2014.
28. **E. Baldini**, S. Sorrenti, C. Tuccilli, N. Prinzi, C. Coccaro, A. Catania, A. Filippini, M. Bononi, E. De Antoni, M. D'Armiento, S. Ulisse: Emerging molecular markers for the prognosis of differentiated thyroid cancer patients. *International Journal of Surgery* 12(Suppl.1):S52-56, 2014.
29. S. Barollo, L. Bertazza, **E. Baldini**, S. Ulisse, E. Cavedon, M. Boscaro, R. Pezzani, C. Mian: The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways. *Investigational New Drugs* 32:626-635, 2014.
30. **E. Baldini**, M. D'Armiento, S. Ulisse: A new Aurora in anaplastic thyroid cancer therapy. *International Journal of Endocrinology* 2014: 816430, 2014.
31. **E. Baldini**, C. Tuccilli, N. Prinzi, S. Sorrenti, A. Antonelli, L. Gnessi, S. Morrone, C. Moretti, M. Bononi, Y. Arlot-Bonnemains, M. D'Armiento, S. Ulisse: Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines. *Endocrine-Related Cancer* 21:797-811, 2014.
32. N. Prinzi, **E. Baldini**, S. Sorrenti, C. De Vito, C. Tuccilli, A. Catania, S. Carbotta, R. Mocini, C. Coccaro, A. Nesca, M. Bianchini, E. De Antoni, M. D'Armiento, S. Ulisse: Thyroid autoantibodies and breast cancer. *Asian Pacific Journal of Cancer Prevention* 15:10999, 2014.
33. **E. Baldini**, C. Tuccilli, N. Prinzi, S. Sorrenti, L. Falvo, C. De Vito, A. Catania, R. Mocini, C. Coccaro, S. Alessandrini, S. Barollo, C. Mian, A. Antonelli, E. De Antoni, M. D'Armiento, S. Ulisse: Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients. *PloS One* 10:e0121514, 2015.
34. N. Prinzi, S. Sorrenti, **E. Baldini**, C. De Vito, C. Tuccilli, A. Catania, C. Coccaro, M. Bianchini, A. Nesca, G. Grani, R. Mocini, E. De Antoni, M. D'Armiento, S. Ulisse: Association of thyroid diseases with primary extra-thyroidal malignancies in women: results of a cross-sectional study of 6,386 patients. *PloS One* 10:e0122958, 2015.
35. S.M. Ferrari, U. Politti, R. Spisni, G. Materazzi, **E. Baldini**, S. Ulisse, P. Miccoli, A. Antonelli, P. Fallahi: Sorafenib in the treatment of thyroid cancer. *Expert Review of Anticancer Therapy* 15:863-874, 2015.
36. C. Tuccilli*, **E. Baldini***, S. Sorrenti, C. di Gioia, D. Bosco, V. Ascoli, C. Mian, S. Barollo, R. Rendina, C. Coccaro, M. Pepe, A. Catania, M. Bononi, F. Tartaglia, E. De Antoni, M.

D'Armiento, S. Ulisse: Papillary thyroid cancer is characterized by the altered expression of genes involved in the sumoylation process. *Journal of Biological Regulators & Homeostatic Agents* 29:655-62, 2015.

* The first two authors provided an equal contribution

37. C. Tuccilli*, **E. Baldini***, N. Prinzi, S. Morrone, S. Sorrenti, A. Filippini, A. Catania, S. Alessandrini, R. Rendina, C. Coccaro, M. D'Armiento, S. Ulisse: Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma derived cell line. *Endocrine* 52:287-95, 2016.
* The first two authors provided an equal contribution
38. S.M. Ferrari, C. La Motta, S. Sartini, **E. Baldini**, G. Materazzi, U. Politte, I. Ruffilli, S. Ulisse, P. Miccoli, A. Antonelli, P. Fallahi: Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer. *Mini-Reviews in Medicinal Chemistry* 16:86-93, 2015.
39. S.M. Ferrari, P. Fallahi, U. Politte, G. Materazzi, **E. Baldini**, S. Ulisse, P. Miccoli, A. Antonelli: Molecular Targeted Therapies of Aggressive Thyroid Cancer. *Frontiers in Endocrinology* 20;6:176, 2015.
40. **E. Baldini**, C. Tuccilli, N. Prinzi, S. Sorrenti, A. Antonelli, P. Fallahi, C. Mian, S. Barollo, A. Catania, S. Morrone, F. Tartaglia, D. Mascagni, C. Coccaro, M. Pepe, A. Filippini, M. D'Armiento, S. Ulisse: Selective inhibitors of aurora kinases inhibit proliferation, reduce cell viability and impair cell cycle progression in papillary thyroid carcinoma cells. *Journal of Biological Regulators and Homeostatic Agents* 29:793-803, 2015.
41. S.M. Ferrari, G. Materazzi, **E. Baldini**, S. Ulisse, P. Miccoli, A. Antonelli, P. Fallahi: Antineoplastic Effects of PPAR γ Agonists, with a Special Focus on Thyroid Cancer. *Current Medicinal Chemistry* 23:636-49, 2016.
42. C. Coccaro, C. Tuccilli, N. Prinzi, E. D'Armiento, M. Pepe, F. Del Maestro, G. Cacciola, B. Forlini, S. Verdolotti, M. Bononi, R. Nacca, **E. Baldini**, G. Cirillo, S. Ulisse: Consumption of iodized salt may not represent a reliable indicator of iodine adequacy: Evidence from a cross-sectional study on schoolchildren living in an urban area of central Italy. *Nutrition* 32:662-6, 2016.
43. R. Pezzani, B. Rubin, L. Bertazza, M. Redaelli, S. Barollo, H. Monticelli, **E. Baldini**, C. Mian, C. Mucignat, C. Scaroni, F. Mantero, S. Ulisse, M. Iacobone, M. Boscaro: The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line. *Investigational New Drugs* 34:531-40, 2016.
44. P. Fallahi, S.M. Ferrari, **E. Baldini**, M. Bircotti, S. Ulisse, G. Materazzi, P. Miccoli, A. Antonelli: The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. *Expert Review of Anticancer Therapy* 16:1109-1118, 2016.
45. S. Sorrenti, **E. Baldini**, F. Tartaglia, A. Catania, S. Arcieri, D. Pironi, P.G. Calò, A. Filippini, S. Ulisse: Nodular thyroid disease in the elderly: novel molecular approaches for the diagnosis of malignancy. *Aging Clinical and Experimental Research* 29(Suppl 1):7-13, 2017.

46. **E. Baldini**, C. Tuccilli, Y. Arlot-Bonnemains, F. Chesnel, S. Sorrenti, C. De Vito, A. Catania, E. D'Armiento, A. Antonelli, P. Fallahi, S. Watutantrige-Fernando, F. Tartaglia, S. Barollo, C. Mian, M. Bononi, S. Arcieri, D. Mascagni, M. Vergine, D. Pironi, M. Monti, A. Filippini, S. Ulisse: Deregulated expression of VHL mRNA variants in papillary thyroid cancer. *Molecular and Cellular Endocrinology* 443:121-127, 2017.
47. C. Tuccilli*, **E. Baldini***, Y. Arlot-Bonnemains, F. Chesnel, S. Sorrenti, C. De Vito, E. D'Armiento, A. Antonelli, P. Fallahi, S. Watutantrige, F. Tartaglia, S. Barollo, C. Mian, M. Bononi, S. Arcieri, D. Mascagni, D. Pironi, M. Vergine, M. Monti, A. Filippini, S. Ulisse: Expression and prognostic value of the cell polarity PAR complex members in thyroid cancer. *International Journal of Oncology* 50:1413-1422, 2017.
* The first two authors provided an equal contribution
48. **E. Baldini**, S. Sorrenti, F. Tartaglia, A. Catania, A. Palmieri, D. Pironi, A. Filippini, S. Ulisse: New perspectives in the diagnosis of thyroid follicular lesions. *International Journal of Surgery* 41:S7-S12, 2017.
49. P. Fallahi, I. Ruffilli, G. Elia, F. Ragusa, S. Ulisse, **E. Baldini**, M. Miccoli, G. Materazzi, A. Antonelli, S.M. Ferrari: Novel treatment options for anaplastic thyroid cancer. *Expert Review of Endocrinology & Metabolism* 12:279-288, 2017.
50. **E. Baldini**, T. Odorisio, S. Sorrenti, A. Catania, F. Tartaglia, G. Carbotta, D. Pironi, R. Rendina, E. D'Armiento, S. Persechino, S. Ulisse: Vitiligo and autoimmune thyroid disorders. *Frontiers in Endocrinology* 8:290, 2017.
51. D. Piccirilli*, **E. Baldini***, M. Massimiani, A. Camaioni, A. Salustri, R. Bernardini, M. Centanni, S. Ulisse, C. Moretti, L. Campagnolo: Thyroid hormone regulates protease expression and activation of Notch signaling in implantation. *Journal of Endocrinology* 236:1-12, 2018.
* The first two authors provided an equal contribution
52. S.M. Ferrari, M. Ferrari, G. Elia, S. Piaggi, **E. Baldini**, S. Ulisse, M. Miccoli, G. Materazzi, A. Antonelli, P. Fallahi: CCL2 is Modulated by Cytokines and PPAR-g in Anaplastic Thyroid Cancer. *Anti-Cancer Agents in Medicinal Chemistry* 18:458-466, 2018.
53. C. Tuccilli*, **E. Baldini***, E. Truppa, B. D'Auria, D. De Quattro, G. Cacciola, T. Aceti, G. Cirillo, A. Faiola, P. Indigeno, L. D'Aliesio, F. Gazzellone, M. Bononi, E. D'Armiento, G. Carbotta, D. Pironi, A. Catania, S. Sorrenti, S. Ulisse: Iodine deficiency in pregnancy: still a health issue for the women of Cassino city. *Nutrition* 50:60-65, 2018.
* The first two authors provided an equal contribution
54. S.M. Ferrari, G. Bocci, T. Di Desidero, I. Ruffilli, G. Elia, F. Ragusa, A. Fioravanti, P. Orlandi, S.R. Paparo, A. Patrizio, S. Piaggi, C. La Motta, S. Ulisse, **E. Baldini**, G. Materazzi, P. Miccoli, A. Antonelli, P. Fallahi: Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. *Oncology Reports* 39:2306-2314, 2018.
55. S.M. Ferrari, G. Bocci, T. Di Desidero, G. Elia, I. Ruffilli, F. Ragusa, P. Orlandi, S.R. Paparo, A. Patrizio, S. Piaggi, C. La Motta, S. Ulisse, **E. Baldini**, G. Materazzi, P. Miccoli, A. Antonelli, P. Fallahi: Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. *Oncology Reports* 39:2225-2234, 2018.

56. C. Tuccilli*, **E. Baldini***, S. Sorrenti, A. Catania, A. Antonelli, P. Fallahi, F. Tartaglia, S. Barollo, C. Mian, A. Palmieri, G. Carbotta, S. Arcieri, D. Pironi, M. Vergine, M. Monti, S. Ulisse: CTLA-4 and PD-1 ligands gene expression in epithelial thyroid cancers. *International Journal of Endocrinology*, 2018: 1742951, 2018.
* The first two authors provided an equal contribution
57. S. Pishkari, M. Paryan, M. Hashemi, **E. Baldini**, S. Mohammadi-Yeganeh: The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies. *J Endocrinol Invest*. 41:269-283, 2018.
58. **E. Baldini**, T. Odorisio, C. Tuccilli, S. Persechino, S. Sorrenti, A. Catania, D. Pironi, G. Carbotta, L. Giacomelli, S. Arcieri, M. Vergine, M. Monti, S. Ulisse: Thyroid diseases and skin autoimmunity. *Reviews in Endocrine and Metabolic Disorders* In press, 2018.
59. S.M. Ferrari, P. Fallahi, I. Ruffilli, G. Elia, F. Ragusa, S.R. Paparo, S. Ulisse, **E. Baldini**, R. Giannini, P. Miccoli, A. Antonelli, F. Basolo: Molecular testing in the diagnosis of differentiated thyroid carcinomas. *Gland Surgery* 7(Suppl.1):S19-S29, 2018.

Publications on national scientific journals

- Calvanese, P. Trimboli, F.M. Graziano, P. Dicorato, A. Di Fiore, **E. Baldini**, D. Pace, M. Dainelli, A. Fumarola, S. Farrace, M. D'Armiento: L'uso del TSH umano ricombinante (rhTSH) nel follow-up del carcinoma differenziato della tiroide. *Giornale di Medicina Militare* 156:245-248, 2006.

Book chapters

- S. Ulisse, **E. Baldini**, S. Bocchini, M. D'Armiento: Plasminogen activating system. In: M. Schwab (ed.): *Encyclopedia of Cancer 2nd Edn.* Springer, 2008, pp 2352-2355.
- E. Baldini**, S. Ulisse, M. D'Armiento: Overexpression of the components of the plasminogen activating system as prognostic factors in human thyroid carcinoma. In: E. Hayat (ed.): *Methods of Cancer Diagnosis, Therapy and Prognosis. General Overviews, Head and Neck Cancer and Thyroid Cancer.* Springer, 2010, pp 445-458.
- S.M. Ferrari, P. Fallahi, **E. Baldini**, S. Ulisse, G. Materazzi, P. Miccoli, A. Antonelli: Tyrosine Kinase Inhibitors; Therapies for Thyroid Cancer. In: Atta-ur-Rahman (ed): *Advances in Genome Science: Genes in Health and Disease, Vol. 4*, 2016, pp 47-61.
- A. Antonelli, **E. Baldini**, S. Sorrenti, P. Fallahi, P. Miccoli, A. Filippini, S. Ulisse: Emerging Therapeutic Approaches for the Most Aggressive Epithelial Thyroid Cancers. In: Hojjat Ahmadzadehfar (ed): *Thyroid Cancer - Diagnosis and Therapy.* InTech, Janeza Trdine, Croatia 2016, pp 171-191.
- E. Baldini**, C. Tuccilli, S. Sorrenti, D. Mascagni, S. Arcieri, A. Filippini, S. Ulisse: Aurora kinases: new molecular targets for the therapy of aggressive thyroid cancers. In: Jasna

Bankovic (ed): *Anti-cancer Drugs - Nature, Synthesis and Cell*. InTech, Janeza Trdine, Croatia 2016, pp 95-118.

6. **E. Baldini**, S. Sorrenti, A. Catania, F. Tartaglia, D. Pironi, M. Vergine, M. Monti, A. Filippini, S. Ulisse: Nodular thyroid disease with aging. In: Shamim Ahmad (ed): *Aging: Exploring a Complex Phenomenon*. Taylor and Francis/CRC Press, Abingdon, UK 2018, pp 247-257.

Communications to national and international congresses

1. S. Ulisse, **E. Baldini**, F.P. Russo, F.M. Graziano, P. Triboli, M. D'Armiento: Espressione differenziale delle metalloproteinasi in diverse linee cellulari di tumori tiroidei. XX Giornate Italiane della Tiroide, Pisa, 5-7 dicembre, 2002. *Atti XX Giornate Italiane della Tiroide* C05, 2002.
2. **E. Baldini**, M. Toller, F.P. Russo, A. Calvanese, F. Curcio, S. Ulisse, F.S. Ambesi-Impiombato, M. D'Armiento: Aumentata espressione della gelatinasi A (MMP-2) e induzione dell'espressione della gelatinasi B (MMP-9) in linee cellulari di tumore differenziato della tiroide: potenziali implicazioni diagnostiche. XXI Giornate Italiane della Tiroide, Chieti, 27-29 novembre 2003. *Atti XXI Giornate Italiane della Tiroide* 38, 2003.
3. **E. Baldini**, M. Toller, F.P. Russo, A. Fumarola, D. Attanasio, F.M. Graziano, P. Trimboli, S. Ulisse, M. D'Armiento: Differential expression of matrix metalloproteinases and plasminogen activators in normal and neoplastic human thyroid cell lines. XXIX Annual Meeting of the European Thyroid Association, Edinburgh, Scotlan, IK, 18-22 ottobre, 2003. *Proceeding of the Annual Meeting of the European Thyroid Association* 36, 2003.
4. **E. Baldini**, M. Toller, E. Marchioni, P. Trimboli, M.F. Graziano, F. Curcio, S. Ulisse, F.S. Ambesi-Impiombato, M. D'Armiento: Post-transcriptional control of urokinase plasminogen activator expression in different cell lines derived from human thyroid tumors. XXIV Giornate Endocrinologiche Pisane, Pisa, 3-5 giugno, 2004. *Journal of Endocrinological Investigation* 27(5): 2, 2004.
5. S. Ulisse, Y Arlot-Bonnemains, J-G Delcros, **E. Baldini**, M. Toller, P. Trimboli, M.F. Graziano, F. Curcio, F.S. Ambesi-Impiombato, M. D'Armiento: Aumentata espressione dei membri della famiglia delle chinasi Aurora nella trasformazione neoplastica del tireocita umano. XXII Giornate Italiane della Tiroide, Salerno, 2-4 dicembre 2004. *Atti XXII Giornate Italiane della Tiroide* 44, 2004.
6. S. Ulisse, J-G Delcros, M. Toller, **E. Baldini**, R. Cavaliere, I.. Coletta, D. Attanasio, F. Curcio, F.S. Ambesi-Impiombato, Y. Arlot-Bonnemains, M. D'Armiento: Expression and cellular localization of the Aurora kinase family members in normal and different human thyroid tumor cell lines. XXXI Congresso Nazionale della Società Italiana di Endocrinologia, Genova, 4-7 maggio 2005. *Journal of Endocrinological Investigation* 28(4): 8, 2005.
7. **E. Baldini**, P. Trimboli, D. Pace, A. Marzullo, A. Fumarola, F.M. Graziano, L. Biordi, P. Dicorato, S. Ulisse, M. D'Armiento: Expression of the components of the plasminogen activating system in benign and malignant thyroid tumor lesions. XXXI Congresso Nazionale della Società Italiana di Endocrinologia, Genova, 4-7 maggio 2005. *Journal of Endocrinological Investigation* 28(4): 113, 2005.

8. S. Ulisse, E. Marchioni, F. Cianfarani, **E. Baldini**, M. Arizzi, N. Moroni, A. Veltri, I. Coletta, A. Di Fiore, M. Teson, T. Odorisio, D. Salvatore, G. Zambruno, M. D'Armiento: Espressione di geni specifici della tiroide nella cute umana. XXIII Giornate Italiane della Tiroide, Torino, 1-3 dicembre, 2005. *Atti XXIII Giornate Italiane della Tiroide* 100, 2005.
9. S. Ulisse, **E. Baldini**, M. Toller, A. Guého, F. Curcio, E. De Antoni, L. Giacomelli, F.S. Ambesi-Impiombato, Y. Arlot-Bonnemains, M. D'Armiento: TACC3 (Transforming Acidic Coiled-Coil 3) e Aurora-A interagiscono nei tireociti umani e la loro espressione è alterata nei tumori differenziati della tiroide. XXIV Giornate Italiane della Tiroide, Modena, 30 novembre – 1 dicembre, 2006. *Atti XXIV Giornate Italiane della Tiroide* 41, 2006.
10. S. Ulisse, J.G. Delcros, **E. Baldini**, M. Toller, F. Curcio, L. Giacomelli, F.S. Ambesi-Impiombato, Y. Arlot-Bonnemains, M. D'Armiento: Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. XXXI Annual Meeting of the European Thyroid Association, Napoli, Italia, 2-6 settembre, 2006. *Proceeding of the Annual Meeting of the European Thyroid Association* 26, 2006.
11. S. Ulisse, **E. Baldini**, E. Marchioni, L. Giacomelli, E. Ferretti, A. Marzullo, F.M. Graziano, P. Trimboli, A. Gulino, M. D'Armiento: Differential expression of the components of the plasminogen activating system in human thyroid papillary carcinomas. XXXI Annual Meeting of the European Thyroid Association, Napoli, Italia, 2-6 settembre, 2006. *Proceeding of the Annual Meeting of the European Thyroid Association* 60, 2006.
12. F. Cianfarani, E. Marchioni, **E. Baldini**, A. Cavalli, M. Teson, G. Zambruno, M. D'Armiento, T. Odorisio, S. Ulisse: Expression and function of thyroid specific genes in human skin. 36th Annual European Society for Dermatological Research Meeting, Parigi, Francia, 7-9 settembre, 2006. *Journal of Investigative Dermatology* 126(Suppl.3):s9, 2006.
13. S. Ulisse, **E. Baldini**, M. Toller, A. Cavalli, A. Guého, F.M. Graziano, S. Bocchini, A. Fumarola, F. Curcio, E. De Antoni, F.S. Ambesi-Impiombato, Y. Arlot-Bonnemains, M. D'Armiento: Transforming acidic coiled-coil 3 and aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. XXXII Congresso Nazionale della Società Italiana di Endocrinologia, Verona, 13-16 giugno 2007. *Journal of Endocrinological Investigation* 30(4): 15, 2007.
14. **E. Baldini**, E. Marchioni, A. Di Benedetto, G. Giovannetti, I. Coletta, A. Di Fiore, D. Pace, E. Petrangeli, S. Sentinelli, R. Perrone Donnorso, M.G. Reale, M. Mottolese, L. Gandini, S. Ulisse, A. Lenzi, M. D'Armiento: Expression of Fas and Fas ligand in human testicular germ cell tumors. XXXII Congresso Nazionale della Società Italiana di Endocrinologia, Verona, 13-16 giugno 2007. *Journal of Endocrinological Investigation* 30(4): 117, 2007.
15. Y. Arlot-Bonnemains, **E. Baldini**, A. Veltri, A. Di Fiore, M. Dainelli, F. Curcio, F.S. Ambesi-Impiombato, S. Ulisse, M. D'Armiento: Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. XXVII Giornate Endocrinologiche Pisane, Pisa, 26-28 giugno, 2008. *Journal of Endocrinological Investigation* 31(4): 8, 2008.
16. S. Ulisse, **E. Baldini**, Y. Arlot-Bonnemains, A. Calvanese, E. Morrone, M. D'Armiento: The Aurora kinase inhibitor MK0457 inhibits cell growth and induces apoptosis of the testicular germ cell cancer-derived cells NT2-D1. XXXIII Congresso Nazionale della Società Italiana di

Endocrinologia, Sorrento, 27-30 maggio 2009. *Journal of Endocrinological Investigation* 32(2):99, 2009.

17. **E. Baldini**, J.C. Gabillard, B. Martin, S. Ulisse, Y. Arlot: Aurora-C and Transforming Acidic Coiled-Coil 1 are expressed in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Mitosis and Cancer Symposium, Amsterdam, 26-27 febbraio, 2009. *Proceeding of the Mitosis and Cancer Symposium* 2, 2009.
18. **E. Baldini**, S. Sorrenti, N. Prinzi, C. Coccaro, G. Grani, R. Mocini, S. Morrone, L. Gnessi, F. Curcio, M. D'Armiento, S. Ulisse: Ultraviolet radiation effects on frtl-5 cell growth and thyroid specific gene expression. XXXVI Congresso Nazionale della Società Italiana di Endocrinologia, Padova, 5-8 giugno, 2013. *Journal of Endocrinological Investigation* 36(5):111, 2013.
19. **E. Baldini**, S. Sorrenti, A. Antonelli, S. Morrone, A. Catania, E. De Antoni, M. D'Armiento, S. Ulisse: Effects of selective aurora-A and aurora-B inhibitors on anaplastic thyroid cancer derived cell lines. XXXVI Congresso Nazionale della Società Italiana di Endocrinologia, Padova, 5-8 giugno, 2013. *Journal of Endocrinological Investigation* 36(5):86, 2013.
20. **E. Baldini**, S. Sorrenti, C. Di Gioia, C. De Vito, A. Antonelli, L. Gnessi, G. Carbotta, A. Nesca, S. Carocci, L. Paone, P. Miccoli, E. De Antoni, M. D'Armiento, S. Ulisse: Cervical lymph node metastases from thyroid cancer: usefulness of thyroglobulin and calcitonin measurement in fine needle aspirates. XXXVI Congresso Nazionale della Società Italiana di Endocrinologia, Padova, 5-8 giugno, 2013. *Journal of Endocrinological Investigation* 36(5):85, 2013.
21. **E. Baldini**, C. Tuccilli, N. Prinzi, M. D'Armiento, S. Ulisse: Alterata espressione dei geni coinvolti nel processo di sumoilazione nel carcinoma papillare della tiroide. XXXVII Congresso Nazionale della Società Italiana di Endocrinologia e XXXI Giornate Endocrinologiche Pisane, Pisa, 10-12 aprile 2014. **Atti delle XXXVII Congresso Nazionale della Società Italiana di Endocrinologia e XXXI Giornate Endocrinologiche Pisane**, 136, 2014.
22. L. Campagnolo, D. Piccirilli, M. Massimiani, **E. Baldini**, S. Ulisse, C. Moretti: Thyroid hormone-regulated molecular mechanisms driving mouse blastocyst implantation. 63rd Congress of the Italian Embryological Group, Rome, 12-15 June 2017. **European Journal of Histochemistry** 61(Suppl. 1):6-7, 2017.
23. **E. Baldini**, E. Testa, F. Cianfarani, C. Voellenkle, F. Martelli, S. Ulisse, T.Odorisio: Dysregulation of MicroRNA biogenesis in diabetic skin. 47th Annual Meeting of the European-Society-for-Dermatological-Research (ESDR), Salzburg, Austria, 27-30 September, 2017. **Journal of Investigative Dermatology** 137(10S, Suppl. 2):S308, 2017.

Roma,20/08/2018

Eulie Baldini